Janus Henderson Group
MNPR icon

Janus Henderson Group’s Monopar Therapeutics MNPR Stock Holding History

Janus Henderson Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.1M Hold
1,317,410
– – 0.03% 342
2025
Q4 		$85.9M Buy
1,317,410
+30,042
+2% +$2.45M 0.04% 314
2025
Q3 		$105M Buy
1,287,368
+115,000
+10% +$5.14M 0.05% 271
2025
Q2 		$41.6M Buy
1,172,368
+37,962
+3% +$1.38M 0.02% 426
2025
Q1 		$45.6M Buy
1,134,406
+87,507
+8% +$3.15M 0.03% 398
2024
Q4 		$23.4M Buy
+1,046,899
New +$17.6M 0.01% 545

Other funds holding MNPR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group's MNPR Position: Q1 2026 in Review

Janus Henderson Group held its Monopar Therapeutics (MNPR) position steady in Q1 2026 at 1,317,410 shares worth $72.1M. The position accounts for 0.03% of the portfolio, ranked #342.

Janus Henderson Group first reported a position in MNPR in Q4 2024 and has held it in 6 quarters since. The position peaked at $105M in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Janus Henderson Group held 1,317,410 shares of Monopar Therapeutics worth $72.1M as of Q1 2026.
  • Janus Henderson Group left its Monopar Therapeutics share count unchanged in Q1 2026.
  • Monopar Therapeutics made up 0.03% of Janus Henderson Group's portfolio in Q1 2026, its #342 holding.
  • Janus Henderson Group first reported a position in Monopar Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Janus Henderson Group's Monopar Therapeutics position peaked at $105M in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.